Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S. [Yahoo! Finance]
Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS)
Last fresenius medical care ag american depositary shares (each representing 1/2 of an ordinary share) earnings: 7/31 04:03 pm
Check Earnings Report
US:NYSE Investor Relations:
freseniusmedicalcare.com/en/investors/investors-overview
Company Research
Source: Yahoo! Finance
The tocilizumab biosimilar provides increased access and an affordable, high-quality, and safe treatment option for U.S. patients. Excellent performance of the (Bio)Pharma business in 2024 so far, also driven by Tyenne ® which became the first tocilizumab biosimilar available in Europe in November 2023. The launch of the tocilizumab biosimilar contributes directly to growing Fresenius' (Bio)Pharma platform, a substantial cornerstone of the #FutureFresenius strategy. BAD HOMBURG, Germany, April 15, 2024 BUSINESS WIRE )--Fresenius, via its operating company Fresenius Kabi, announced today the immediate U.S. availability of Tyenne ® (tocilizumab-aazg), a biosimilar of Actemra ® (tocilizumab). Tyenne ® , for use in the treatment of chronic autoimmune diseases, is available in an intravenous (IV) formulation. Michael Sen, CEO of Fresenius: "With the launch of Tyenne ® in the U.S., we have reached another important milestone in accelerating our strong (Bio)Pharma momentum. Growing
Show less
Read more
Impact Snapshot
Event Time:
FMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FMS alerts
High impacting Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) news events
Weekly update
A roundup of the hottest topics
FMS
News
- Global Hemodialysis and Peritoneal Dialysis Research Report 2024-2029: Increasing Growth Opportunities in Emerging Economies, Rising Number of Dialysis Centers, Growing Preference for Home Care [Yahoo! Finance]Yahoo! Finance
- Fresenius Medical Care AG (NYSE: FMS) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.MarketBeat
- Fresenius Medical Care (ETR:FME) earnings and shareholder returns have been trending downwards for the last five years, but the stock soars 14% this past week [Yahoo! Finance]Yahoo! Finance
- Fresenius Medical Care AG (NYSE: FMS) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
- Dialysis Machines Market Analysis Forecast to 2033 - Technological Innovations and Global Market Trends [Yahoo! Finance]Yahoo! Finance
FMS
Earnings
- 8/3/23 - In-Line
FMS
Sec Filings
- 3/28/24 - Form 6-K
- 3/13/24 - Form 6-K
- 3/5/24 - Form 6-K
- FMS's page on the SEC website